Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-30 @ 9:32 AM
Study NCT ID:
NCT01137994
Status:
WITHDRAWN
Last Update Posted:
2013-03-13
First Post:
2010-06-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-10
Start Date Type:
None
Primary Completion Date:
2016-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2018-03
Completion Date Type:
ESTIMATED
First Submit Date:
2010-06-03
First Submit QC Date:
None
Study First Post Date:
2010-06-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-03-11
Last Update Post Date:
2013-03-13
Last Update Post Date Type:
ESTIMATED